The initial closing includes commitments to fund USD 12.8m.
These funds will enable the company to conduct a Phase 2b BPZE1 clinical study following the Phase 2a study currently in progress at the Vanderbilt Vaccine Research Program.
The Class C financing is led by Network-1 Technologies (NYSE American: NTIP) and SDS Capital Partners. Existing shareholders JEMS Venture Capital and Seedlings Life Science Ventures also participated in the committed financing.
With the addition of the current commitments, the company has now secured USD 23m in equity funding since inception. Including a previous European grant of EUR 10m and upon completion of the Class C financing, assuming the maximum offering is consummated, a cumulative USD 41m will have been raised to develop ILiAD's BPZE1 technology.
BPZE1 is the most advanced next generation pertussis vaccine in the world, designed to overcome deficiencies of current vaccines, including poor durability and failure to prevent nasopharyngeal Bordetella pertussis infections that lead to transmission to vulnerable infants.
Earlier this year, the FDA cleared the Investigational New Drug application for a Phase 2a BPZE1 study at the Vanderbilt Vaccine and Treatment Evaluation Unit, sponsored by the National Institute of Allergy and Infectious Disease (NIAID) at the National Institute of Health.
BPZE1 was developed in the lab of Camille Locht, PhD, at the Institut Pasteur de Lille and French National Institute of Health and Medical research.
ILiAD holds exclusive global rights to BPZE1 and related B-Tech technologies that are covered by 34 issued patents. An additional 24 patents are pending around the world.
In addition to funding continued operations, R and D and manufacturing development, the financing will support further clinical studies, including a multicenter Phase 2b clinical study that will compare ILiAD's lead candidate vaccine, BPZE1, to Boostrix, an FDA-licensed intramuscular acellular pertussis vaccine. It is anticipated that the Phase 2b study will enroll up to 300 healthy adult volunteers.
Walter Greenblatt and Associates, LLC (member FINRA, SIPC), a life science-focused investment bank, served as the financial advisor to ILiAD for this financing as well as for ILiAD's prior financing rounds.
BPZE1 is a next-generation live-attenuated pertussis vaccine designed to induce comprehensive and durable protection against B. pertussis infection (colonization) and disease (whooping cough).
BPZE1 is being developed to block B. pertussis from colonizing the adult nasal passage, protecting adults and adolescents, and potentially preventing transmission, including transmission to infants.
While ILiAD is currently focused on developing a vaccine to directly protect adults and adolescents and to indirectly protect vulnerable infants, future development aims to immunise neonates directly.
Poolbeg PHarma plc receives notice of allowance for POLB 001 patent
RedHill Biopharma secures USPTO Patent for Talicia, extending protection through 2034
Micron Biomedical names new scientific advisor to CEO
Quanterix partners with leading health networks for Alzheimer's diagnosis advancements
Precision BioSciences reports FDA pre-IND feedback for PBGENE-HBV
VBI to sell manufacturing capabilities and enter new license agreement with Brii Biosciences
Ondine Biomedical's Steriwave shows promise in nasal pathogen reduction
BioSenic expands patent coverage for ATO therapeutic platform
PacBio unveils Nanobind PanDNA kit for enhanced DNA extraction solutions
Sequentify receives funding from Israel Innovation Authority
INOVIO plans BLA submission for INO-3107 as RRP treatment
ImmunityBio secures USD320m investment from Oberland Capital
Poolbeg Pharma prioritises promising RSV drug candidates identified through AI-led analysis
GHIT fund invests JPY500m in antimalarial drug clinical trial